Müller D - Search Results

1

A humanized tumor necrosis factor receptor 1 (TNFR1)-specific antagonistic antibody for selective inhibition of tumor necrosis factor (TNF) action.

Kontermann RE, Münkel S, Neumeyer J, Müller D, Branschädel M, Scheurich P, Pfizenmaier K. Kontermann RE, et al. Among authors: muller d. J Immunother. 2008 Apr;31(3):225-34. doi: 10.1097/CJI.0b013e31816a88f9. J Immunother. 2008. PMID: 18317365

2

Generation of human high-affinity antibodies specific for the fibroblast activation protein by guided selection.

Schmidt A, Müller D, Mersmann M, Wüest T, Gerlach E, Garin-Chesa P, Rettig WJ, Pfizenmaier K, Moosmayer D. Schmidt A, et al. Among authors: muller d. Eur J Biochem. 2001 Mar;268(6):1730-8. Eur J Biochem. 2001. PMID: 11248693 Free article.

3

Generation of a FasL-based proapoptotic fusion protein devoid of systemic toxicity due to cell-surface antigen-restricted Activation.

Samel D, Muller D, Gerspach J, Assohou-Luty C, Sass G, Tiegs G, Pfizenmaier K, Wajant H. Samel D, et al. Among authors: muller d. J Biol Chem. 2003 Aug 22;278(34):32077-82. doi: 10.1074/jbc.M304866200. Epub 2003 May 28. J Biol Chem. 2003. PMID: 12773535 Free article.

4

Restoration of membrane TNF-like activity by cell surface targeting and matrix metalloproteinase-mediated processing of a TNF prodrug.

Gerspach J, Müller D, Münkel S, Selchow O, Nemeth J, Noack M, Petrul H, Menrad A, Wajant H, Pfizenmaier K. Gerspach J, et al. Among authors: muller d. Cell Death Differ. 2006 Feb;13(2):273-84. doi: 10.1038/sj.cdd.4401735. Cell Death Differ. 2006. PMID: 16052236

5

Generation of immunoliposomes using recombinant single-chain Fv fragments bound to Ni-NTA-liposomes.

Rüger R, Müller D, Fahr A, Kontermann RE. Rüger R, et al. Among authors: muller d. J Drug Target. 2005 Aug;13(7):399-406. doi: 10.1080/10611860500353328. J Drug Target. 2005. PMID: 16308208

6

In vitro characterization of binding and stability of single-chain Fv Ni-NTA-liposomes.

Rüger R, Müller D, Fahr A, Kontermann RE. Rüger R, et al. Among authors: muller d. J Drug Target. 2006 Sep;14(8):576-82. doi: 10.1080/10611860600864018. J Drug Target. 2006. PMID: 17050123

7

Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin.

Müller D, Karle A, Meissburger B, Höfig I, Stork R, Kontermann RE. Müller D, et al. J Biol Chem. 2007 Apr 27;282(17):12650-60. doi: 10.1074/jbc.M700820200. Epub 2007 Mar 8. J Biol Chem. 2007. PMID: 17347147 Free article.

8

Single-chain Fv immunoliposomes for the targeting of fibroblast activation protein-expressing tumor stromal cells.

Baum P, Müller D, Rüger R, Kontermann RE. Baum P, et al. Among authors: muller d. J Drug Target. 2007 Jul;15(6):399-406. doi: 10.1080/10611860701453034. J Drug Target. 2007. PMID: 17613658

9

Recombinant bispecific antibodies for cellular cancer immunotherapy.

Müller D, Kontermann RE. Müller D, et al. Curr Opin Mol Ther. 2007 Aug;9(4):319-26. Curr Opin Mol Ther. 2007. PMID: 17694444 Review.

10

A novel tri-functional antibody fusion protein with improved pharmacokinetic properties generated by fusing a bispecific single-chain diabody with an albumin-binding domain from streptococcal protein G.

Stork R, Müller D, Kontermann RE. Stork R, et al. Among authors: muller d. Protein Eng Des Sel. 2007 Nov;20(11):569-76. doi: 10.1093/protein/gzm061. Epub 2007 Nov 3. Protein Eng Des Sel. 2007. PMID: 17982179

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

5,003 results

Search Page

Filters